[{"arm_notes": "", "treatment_id": null, "treatment_name": "Four vaccine candidates selected for evaluation. Candidate vaccines are selected on a rolling basis by the WHO Working Group on vaccine prioritization Trial entry; randomization: Once electronic data collection has been completed the volunteer automatically enters the trial and a random allocation of their trial vaccine is generated (by an algorithm that ensures eventual balance in the characteristics just recorded between each study vaccines and its placebos) and displayed. The volunteers will be randomly allocated either to placebo or to one of the study vaccines. Follow-up: Each participant will be contacted weekly for 52 weeks for information as to whether any potentially relevant symptoms have arisen; with laboratory testing triggered if the report suggests COVID-19. Adaptive design: A global Data Monitoring Committee will keep the accumulating safety results and major outcome results under regular review. Different candidate vaccines may be available or suitable to enter the trial at different times; for each candidate vaccine; the primary efficacy results are expected within 3-6 months of the vaccine entering the trial. By using a shared placebo/control group and a common Core protocol to evaluate multiple candidate vaccines in the trial; resources allocated to the evaluation of each candidate vaccine are judiciously saved while a high standard of scientific rigor and efficiency is ensured. Add-on studies: Particular countries; or particular groups of sites; may want to collaborate in making further measurements or observations. These could be thought of as Phase 2b trials that are being conducted concurrently with the Phase 3 trial. However; while well-organised additional resea", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "1, IM", "treatment_id": 1901, "treatment_name": "Arct-021", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1 or 2, Nasal", "treatment_id": 349, "treatment_name": "Covi-vac", "treatment_type": "Live attenuated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2, IM", "treatment_id": 653, "treatment_name": "Ino-4800", "treatment_type": "Dna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2, IM", "treatment_id": 840, "treatment_name": "Mvc-cov1901", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]